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Matriptase-2, encoded by theTMPRSS6 gene, is a member of the type II transmembrane
serine protease family. Matriptase-2 has structural and enzymatic similarities to matriptase-
1, which has been implicated in cancer progression. Matriptase-2 was later established to
be essential in iron homeostasis based on the phenotypes of iron-refractory iron deﬁciency
anemia identiﬁed in mouse models as well as in human patients withTMPRSS6 mutations.
TMPRSS6 is expressed mainly in the liver and negatively regulates the production of
hepcidin, the systemic iron regulatory hormone. This review focuses on the current
understanding of matriptase-2 biochemistry, and its role in iron metabolism and cancer
progression. In light of recent investigations, the function of matriptase-2 in hepcidin
regulation, how it is being regulated, as well as the therapeutic potential of matriptase-2
are also discussed.
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BIOCHEMISTRY OF MATRIPTASE-2
Type II transmembrane serine protease matriptase-2, encoded by
the TMPRSS6 gene, belongs to the family of type II transmem-
brane serine proteases (TTSP). Matriptase-2 is comprised of a
transmembrane domain, followed by a sea urchin sperm pro-
tein, enteropeptidase and agrin (SEA) domain, a stem region
containing two complement factor C1r/C1s, urchin embryonic
growth factor and bone morphogenetic protein (CUB) domains
and three low-density lipoprotein receptor (LDLR) class A repeats,
and a C-terminal trypsin-like serine protease domain (Velasco
et al., 2002; Ramsay et al., 2008). Matriptase-2 is synthesized as
a single chain inactive proenzyme, which auto-activates itself by
a cleavage at an arginine residue at the RIVGG consensus site
between the prodomain and the catalytic domain (Ramsay et al.,
2009b; Altamura et al., 2010). After the auto-activation, it remains
membrane-bound through a single disulphide bond linking the
pro- and catalytic domains (Ramsay et al., 2009a). Once the cat-
alytic domain is released, it migrates as a single or dimeric species
(Silvestri et al., 2008). Matriptase-2 shares high structural and
enzymatic similarities with matriptase-1, which contains four
LDLR repeats instead of three (Sanders et al., 2010), is expressed
in epithelial cells, and has been implicated in the progression of
cancers, such as breast, prostate, and colorectal cancer (Oberst
et al., 2001; Velasco et al., 2002; Kang et al., 2003; Riddick et al.,
2005).
The structural features of matriptase-2 are highly conserved
across mammalian species, including human, macaque monkey,
dog, cow, mouse and rat, with human protein sharing >80%
identity to matriptase-2 from other species (Ramsay et al., 2008).
The expression pattern of TMPRSS6 determined from mRNA
expression studies and analysis of GenBankUnigenedatabase indi-
cates that matriptase-2 is predominantly expressed in the liver
(Velasco et al., 2002; Finberg et al., 2008) but also to a lower extent
in the kidney, spleen, brain, lung, mammary gland, testis, and
uterus (Ramsay et al., 2008). In addition, aberrant expression of
TMPRSS6 is observed in different human cancers such as breast
and prostate cancer (Parr et al., 2007; Sanders et al., 2008).
Matriptase-1, a close relative of matriptase-2, is known
to be associated with two endogenous inhibitors: hepatocyte
growth factor activator inhibitor (HAI)-1 and HAI-2, which
inhibit matriptase-1 dependent activation of its physiological
substrates, likely through an interaction with the second CUB
domain (Szabo et al., 2008; Inouye et al., 2010). With 35% iden-
tity and structural similarities with matriptase-1 (Velasco et al.,
2002), it is possible that matriptase-2 is also associated with
an endogenous inhibitor. Indeed, Maurer et al. (2013) recently
demonstrated that HAI-2 is a cognate inhibitor of matriptase-2
that inhibits its proteolytic activity, and thus increases hepcidin
expression in vitro. However, the physiological role of HAI-2 in
the regulation of hepcidin and iron metabolism remains to be
investigated.
Following the identiﬁcation and characterization of matrip-
tase-2, Velasco et al. (2002) also examined the enzymatic activity
of the catalytic serine protease domain against extracellularmatrix
components. It was found that matriptase-2 has the capacity to
degrade ﬁbronectin, ﬁbrinogen, and type I collagen. Recently,
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membrane bound hemojuvelin has also been identiﬁed as a sub-
strate for matriptase-2 in vitro (Silvestri et al., 2008), providing a
straightforwardmechanism for the effects of TMPRSS6 mutations
on hepcidin and iron regulations. However, as will be discussed
below, evidence exists in vivo that is not consistent with this
hypothesis.
ROLE OF MATRIPTASE-2 IN IRON METABOLISM
Matriptase-2 is produced mainly by the liver and negatively reg-
ulates the production of hepcidin, the systemic iron regulatory
hormone encoded by the HAMP gene (Du et al., 2008; Finberg
et al., 2008). Hepcidin is a peptide secreted by the liver that plays a
central role in adjusting iron absorption to meet iron needs of the
body (Nicolas et al., 2001). Hepcidin negatively regulates cellular
iron export by promoting the degradation of ferroportin (Nemeth
et al., 2004), the only known iron exporter present on the surface
of duodenal enterocytes, macrophages, and hepatocytes and thus
limits iron absorption and iron release. It is now well established
that Hamp expression is regulated by the bone morphogenetic
protein (BMP)/sons of mothers against decapentaplegic (SMAD)
signaling pathway (Babitt et al., 2006, 2007).
At the molecular level, BMP6, the endogenous ligand of
BMP/SMAD signaling, activates BMP-receptor complex by bind-
ing to type I and type II BMP receptors that induces phospho-
rylation (Andriopoulos et al., 2009; Meynard et al., 2009). The
activated complex, in turn, phosphorylates Smad1,5,8/Smad4
complex, which then translocates to nucleus to modulate gene
transcription (Wang et al., 2005; Babitt et al., 2006; Kautz
et al., 2008). Hemojuvelin (HJV) acts as a coreceptor and is
required to fully activate the BMP signaling ability (Babitt et al.,
2006). The expression of BMP6 is proportional to hepatic iron
concentrations and consistent with Hamp mRNA expression
(Kautz et al., 2008).
TMPRSS6 MUTATIONS IN MICE AND HUMAN
Matriptase-2 regulatesHamp expression through the BMP/SMAD
pathway (Finberg et al., 2010; Lenoir et al., 2011) in an as
yet unfully characterized manner. Mice without functional
matriptase-2 (both mask mice with truncated Tmprss6 lacking
the protease domain and Tmprss6 knockout mice) showed a
hypochromic microcytic anemia and an alopecia (Du et al., 2008;
Folgueras et al., 2008). These phenotypes resulted from inappro-
priately high levels of Hamp mRNA expression (Du et al., 2008;
Folgueras et al., 2008; Finberg et al., 2010).
Mutations in TMPRSS6 in humans led to iron-refractory iron
deﬁciency anemia (IRIDA) that is unresponsive to oral iron
treatment and only partially responsive to parental iron therapy
(Finberg et al., 2008). IRIDA is also characterized by congen-
ital hypochromic, microcytic anemia, low mean corpuscular
erythrocyte volume, low transferrin saturation, and defects in
iron absorption and utilization (Finberg et al., 2008; Guillem
et al., 2008; Melis et al., 2008). Currently, there are 42 different
TMPRSS6 mutations reported in humans, scattered throughout
all the different extracellular domains (Figure 1).
Interestingly, in contrast to current understanding of auto-
somal recessive disorder, haploinsufﬁciency is observed in some
TMPRSS6 mutations (Figure 1; Finberg et al., 2008; Pellegrino
et al., 2012; Jaspers et al., 2013). Haploinsufﬁciency is also observed
in animal models. Nai et al. (2010) reported that Tmprss6 het-
erozygous knockout mice are more susceptible to iron deﬁciency
compared to their wild-type littermates. Finberg et al. (2011)
also demonstrated that, compared to mice deﬁcient for Hfe
alone, heterozygous loss of Tmprss6 in Hfe knockout mice had
higher hepcidin levels at 4 weeks of age, which presumably
resulted in decreased hepatic iron concentrations at 8 weeks
of age.
Human genome wide association studies (GWAS) highlighted
the signiﬁcance of matriptase-2 in control of iron homeostasis by
identifying common TMPRSS6 variants associated with abnor-
mal hematological parameters, including hemoglobin, transferrin
saturation, erythrocyte mean cell volume (MCV) and serum
iron concentrations (Benyamin et al., 2009; Chambers et al.,
2009; Tanaka et al., 2010). Following GWAS, population-based
cohort studies were investigated in China and Italy to study
the association between serum iron parameters, iron-related dis-
eases and speciﬁc TMPRSS6 single nucleotide polymorphisms
(SNPs): rs855791 (V736A) and rs4820268 (D521D). It was found
that TMPRSS6 SNPs was associated with lowered serum iron,
hemoglobin, and plasma ferritin levels, consistent with lowered
risk of iron overload and increased risk of iron deﬁciency ane-
mia in Chinese population (An et al., 2012; Gan et al., 2012). A
retrospective cohort study in northern Italy also suggested that
TMPRSS6 V736A polymorphism is likely to be a gene modi-
ﬁer in hemochromatosis patients, inﬂuencing the susceptibility
of cirrhosis (Valenti et al., 2012). Nai et al. (2011) demonstrated
that TMPRSS6 V736A directly modulates HAMP expression in
vitro and that healthy individuals with the homozygous sub-
stitution had lower levels of serum hepcidin, higher serum
iron and higher transferrin saturation. Taken together, these
studies clearly establish TMPRSS6/matriptase-2 as an impor-
tant regulator of iron homeostasis in humans. A recent review
focused more on the anemia induced by matriptase-2 muta-
tions is complementary to the current review (De Falco et al.,
2013).
FUNCTION OF MATRIPTASE-2 IN HEPCIDIN REGULATION
Matriptase-2 inhibition of hepcidin activation by cleaving mem-
brane hemojuvelin has been established in vitro (Silvestri et al.,
2008). When overexpressed in HeLa cells, matriptase-2 interacts
and induces the cleavage of membrane hemojuvelin at the cell
surface, resulting in the generation of soluble hemojuvelin that is
released into the cell medium (Silvestri et al., 2008). However, in
bothmask andTmprss6 knockoutmice, hepatic hemojuvelin levels
at the membrane were found unexpectedly to be decreased, com-
pared towild-type animals (Krijt et al., 2011; Frydlova et al., 2013).
In addition, the levels of serum soluble hemojuvelin, which one
would expect to be decreased in Tmprss6 knockout, did not differ
from wild-type mice (Chen et al., 2013). Although the possibil-
ity that soluble hemojuvelin and fragments are rapidly degraded
in vivo cannot be excluded, these data suggested that hemoju-
velin may not be the endogenous substrate of matriptase-2 and
that matriptase-2 functions in a more complicated way in vivo
than by merely cleaving hemojuvelin to regulate hepcidin and
iron.
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FIGURE 1 |TMPRSS6 gene structure and schematic representation of
corresponding matriptase-2 mutations reported in IRIDA patients.The
genomic organization and the corresponding structural domains of
matriptase-2 with currently identiﬁed mutations are shown. The missense,
nonsense, frameshift and splice junction mutations are shown in green, blue,
red and purple arrows, respectively. One in-frame deletion is boxed in gray.
The mutations highlighted in red represent those appear to have
haploinsufﬁciency.
Several studies have been conducted to study the role of
matriptase-2, by crossingTmprss6 knockoutmicewith several iron
overloadmousemodels, including the generations ofHjv/Tmprss6,
Bmp6/Tmprss6, Hfe/Tmprss6, and Tfr2/Tmprss6 double mutant
mice (Truksa et al., 2009; Finberg et al., 2011; Lenoir et al., 2011;
Lee et al., 2012). In mice lacking both Hjv and Tmprss6, Id1, a
target gene of BMP6 signaling, and Hamp mRNA levels were low,
whereas serum iron, transferrin saturation, and liver iron con-
centration were high, similar to phenotypes of mice deﬁcient for
Hjv alone (Truksa et al., 2009; Finberg et al., 2010). These results
indicate that if the substrate of matriptase-2 is downstream of
hemojuvelin, it is likely to be along the SMAD signaling pathway.
It is known that inﬂammatory cytokines, such as LPS and IL6,
can induce Hamp expression in the absence of Hjv (Niederkoﬂer
et al., 2005), presumably via the Stat3 and Stat5 pathways (Verga
Falzacappa et al., 2007; Meynard et al., 2013). However, it was sur-
prising to ﬁnd that the lack of both Hjv and Tmprss6 in mice
did not impair the responsiveness of hepcidin to BMP2 and IL6,
but did fail to respond to iron challenge (Truksa et al., 2009). In
mice deﬁcient for both Bmp6 andTmprss6, the levels of Hamp and
Id1 mRNAs did not differ from mice deﬁcient for Bmp6 alone;
however, their plasma iron levels and hepatic iron stores were sig-
niﬁcantly lower, suggesting the loss of matriptase-2 ameliorates
iron overload conditions in Bmp6 knockout mice (Lenoir et al.,
2011). It is unclear why Bmp6/Tmprss6 mice had less iron loading
compared to mice deﬁcient for Bmp6 alone, but Hamp mRNA
levels did not differ between Bmp6/Tmprss6 and Bmp6 knock-
out mice. Whether matriptase-2 has a signiﬁcant role besides
effects on BMP/SMAD signaling in iron metabolism, remain to
be investigated.
Mice deﬁcient for Hfe or Tfr2 alone also develop iron overload
phenotypes with inappropriately low Hamp mRNA expression
and high serum iron parameters, compared to wild-type ani-
mals (Ahmad et al., 2002; Wallace et al., 2005). It is suggested
that Hfe competes with transferrin for binding to transferrin
receptor-1 and thus inhibits Hamp expression (Giannetti and
Bjorkman,2004; Schmidt et al., 2008). Others also showed thatHfe
knockout mice had high Bmp6 mRNA expression but inappropri-
ately low Smad1/5/8 phosphorylation, suggesting Hfe facilitates
signal transduction initiated by BMP6 (Corradini et al., 2009;
Kautz et al., 2009). However, the underlying mechanisms of how
Hfe and Tfr2 contribute in BMP/SMAD signaling pathway is
unclear. Mice deﬁcient for both Hfe or Tfr2 and Tmprss6, had high
Hamp mRNA expression and exhibited iron deﬁciency micro-
cytic anemiamimicking the phenotypes of mice lacking functional
matriptase-2 alone (Finberg et al., 2011; Lee et al., 2012). This sug-
gests that Hfe and Tfr2, if involved in BMP/SMAD pathway, are
likely to be upstream of matriptase-2 signaling.
REGULATION OF MATRIPTASE-2
Studies have shown that matriptase-2 expression can be mod-
ulated by iron status (Meynard et al., 2011; Zhang et al., 2011).
In rats under acute iron deprivation, hepatic matriptase-2
protein levels are upregulated to repress hepcidin production
(Zhang et al., 2011). Interestingly, matriptase-2 levels are also
increased in response to chronic iron treatment and BMP6
administration in mice, possibly to prevent excessive hepcidin
production, suggesting a dual role of matriptase-2 in the main-
tenance of tight systemic iron balance in response to iron
(Meynard et al., 2011). In addition, studies also suggest that
TMPRSS6 mRNA expression is suppressed by conditions of
inﬂammation (Meynard et al., 2013) and is upregulated inhypoxia
(Lakhal et al., 2011; Maurer et al., 2012) and by erythropoi-
etin (Peng et al., 2010). Human hepatoma Hep3B cells treated
with interleukin-6 and mice injected with lipopolysaccharide
demonstrated a downregulation of TMPRSS6 via a decrease
in Stat5 phosphorylation, independent of BMP/SMAD path-
way (Meynard et al., 2013). Studies using Hep3B cells revealed
that TMPRSS6 is upregulated by HIF-1α and HIF-2α. This
upregulation resulted in a decrease in membrane hemojuvelin
and thus reducing hepcidin production (Lakhal et al., 2011). In
mice, Tmprss6 mRNA expression is induced by erythropoietin
(Peng et al., 2010), which is also shown to be a negative regu-
lator of hepcidin expression (Sasaki et al., 2012). Whether the
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downregulation of hepcidin by erythropoietin is dependent on
Tmprss6 or through other unidentiﬁed mechanisms remains to be
investigated.
MATRIPTASE-2 AS A THERAPEUTIC TARGET
Genetic studies of mice deﬁcient for both Tmprss6 and Hfe or
Tfr2 or Hbbth3/+, the mouse model of β-thalassemia interme-
dia, have shown that iron overload can be prevented by targeting
Tmprss6 (Finberg et al., 2011; Lee et al., 2012; Nai et al., 2012). It
is believed that the therapeutic effect did not come from silenc-
ing Tmprss6 directly but from increased hepcidin production,
resulting in lowered circulating iron burden (Camaschella, 2013).
Studies targeting Tmprss6 in Hbbth3/+ and Hfe knockout mice
by injecting silencing RNA (Schmidt et al., 2013) and anti-sense
oligonucleotides (Guo et al., 2013) have successfully suppressed
Tmprss6 mRNA expression, leading to elevated hepcidin lev-
els, improved iron overload in Hfe knockout and anemia and
β-thalassemicmice. It is unclear how the ineffective erythropoiesis
is improved by dampening Tmprss6 expression in Hbbth3/+ mice.
However, higher hepcidin level inhibiting iron delivery to the ery-
throid precursors seems to play a role as evident by the similar
effects achieved by overexpression of Hamp, iron restriction, and
the injection of transferrin to Hbbth3/+ mice (Gardenghi et al.,
2010; Li et al., 2010; Finberg, 2013).
One limitation of using this method is that, unlike tradi-
tional phlebotomy and chelation therapies, iron is not removed
or excreted from the body, and therefore, may not be an ideal
treatment for patients with severe iron overload and transfusion-
dependent thalassemia (Camaschella, 2013). It could, however,
improve therapeutic efﬁcacy when used in combination with
other traditional therapies by preventing intestinal iron absorp-
tion. A key issue for the use of RNA interference for clinical
applications is the delivery method. There are safety concerns
with viral vectors and non-viral delivery methods, which are
still in their early development stage. Concerns have also been
raised regarding the potential for off-target effects of siRNAs and
their possible induction of interferon-stimulated genes. Other
novel inhibitors of TMPRSS6, such as small molecule inhibitors,
once identiﬁed, may eventually become useful therapeutic agents
as well.
ROLE OF MATRIPTASE-2 IN CANCER
Numerousmembers of the type II transmembrane serine protease
family have been associated with a variety of different human can-
cers due to the differential expression patterns observed in these
proteases between normal and cancerous tissues and cells (Webb
et al., 2011). However, there are only a limited number of stud-
ies examining the involvement of matriptase-2 in human cancer,
including breast cancer (Hartikainen et al., 2006; Parr et al., 2007;
Tuhkanen et al., 2013) and prostate cancer (Sanders et al., 2008;
Webb et al., 2012).
The association between matriptase-2 and breast cancer was
established by a case control study in eastern Finnish population
where they found a SNP (rs733655) in TMPRSS6 gene associ-
ated with increased breast cancer risk (Hartikainen et al., 2006). It
was later shown that TMPRSS6 mRNA expression inhibits breast
tumor development and thus correlates with favorable prognostic
outcome in patients (Parr et al., 2007). Recently, Tuhkanen et al.
(2013) also demonstrated the association of several TMPRSS6
variants with breast cancer risk and survival. It was highlighted
that matriptase-2 protein levels decrease with tumor progression,
and lower gene expression is seen in poor-prognosis-related triple-
negative breast cancers (Tuhkanen et al., 2013). Mastriptase-2 is
also implicated in tumor invasion and metastasis in prostate can-
cer in vitro (Sanders et al., 2008; Webb et al., 2012). These results
indicate the involvement of matriptase-2 in tumor development.
However, it is not clear whether the role of TMPRSS6 in can-
cer progression is due to its ability to cleave extracellular matrix
component such as ﬁbronectin or due to a modiﬁcation of iron
parameters in cancer cells.
TMPRSS6 expression is predominantly found in low invasive
breast cancer cell lines such as MCF-7 and is absent in more
invasive breast cancer cell lines such as MDA-MB-231 (Parr et al.,
2007). Overexpression of matriptase-2 in MDA-MB-231 leads to
a reduction of invasiveness and motility of the transfected cells
and suppresses their tumorigenesis when xenografted in athymic
nude mice suggesting that matriptase-2 could be involved in can-
cer progression through its capacity to cleave extracellular matrix
components (Parr et al., 2007). However, variations of the iron
status and iron regulatory genes expression were not addressed in
the transfected cells in this study.
Many cancers exhibit an increased requirement for iron, pre-
sumably because of the need for iron as a cofactor in proteins
essential to sustain growth and proliferation. The iron exporter
ferroportin is expressed in breast cancer cells. Pinnix et al. (2010)
showed that cells with high hepcidin and low ferroportin lev-
els tended to be more aggressive. They concluded that having a
breast cancer with low hepcidin and high ferroportin levels is an
independent predictor of prognosis for a >90% 10-year survival
rate (Pinnix et al., 2010), however, the mechanism is still to be
investigated. Further studies are required to clarify the role of
matriptase-2 in cancer progression.
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